Europe · Regional markets · Option Finance

TME Pharma : perte semestrielle réduite, visibilité financière prolongée

Published by Option Finance · France 10 h ago

La société de biotechnologie a fortement réduit ses dépenses au premier semestre 2026. Elle mise désormais sur un partenariat avec le japonais TMS pour relancer le développement…

Read the full article on Option Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.optionfinance.fr)

Also worth reading

This is Money

As investors brace themselves for a market meltdown, experts reveal the best ways to keep your wealth growing - from the areas to invest your cash to the simple ground rules you MUST follow

City A.M.

Revealed: The luxury London pads getting Healey’s energy handout – while poorer areas miss out

Finews

TME Pharma : perte semestrielle réduite, visibilité financière prolongée

Share

Also worth reading

As investors brace themselves for a market meltdown, experts reveal the best ways to keep your wealth growing - from the areas to invest your cash to the simple ground rules you MUST follow

Revealed: The luxury London pads getting Healey’s energy handout – while poorer areas miss out

BNP Paribas appoints new head of Securities Services Switzerland

BP slashes debt as it rationalises its portfolio

How being single can lead to a higher inheritance tax bill

French Tech : l’IA concentre plus de 90 % des 41 millions d’euros levés cette semaine